<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90765748-00A7-4D14-9C5F-F34DA45F3D55"><gtr:id>90765748-00A7-4D14-9C5F-F34DA45F3D55</gtr:id><gtr:name>Western University</gtr:name><gtr:address><gtr:line1>Western University Main Campus</gtr:line1><gtr:line2>#3, Street 528</gtr:line2><gtr:line3>Sangkat Boeung Kok I, Khan Tuol Kork</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90765748-00A7-4D14-9C5F-F34DA45F3D55"><gtr:id>90765748-00A7-4D14-9C5F-F34DA45F3D55</gtr:id><gtr:name>Western University</gtr:name><gtr:address><gtr:line1>Western University Main Campus</gtr:line1><gtr:line2>#3, Street 528</gtr:line2><gtr:line3>Sangkat Boeung Kok I, Khan Tuol Kork</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D6784BA3-960E-40CB-8663-A597913E4CF5"><gtr:id>D6784BA3-960E-40CB-8663-A597913E4CF5</gtr:id><gtr:firstName>D</gtr:firstName><gtr:surname>Higgs</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137961147"><gtr:id>2C58CC13-2D03-48D5-B99F-431BD4DFB540</gtr:id><gtr:title>The ATRX programme</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137961147</gtr:grantReference><gtr:abstractText>Despite the revolution in genetics in the last decade and in particular the sequencing of the human genome, the regulation of gene expression largely remains a mystery. Every cell of the body contains a full complement of genes but only expresses a small repertoire required for that tissues function, such as the oxygen carrying protein, haemoglobin, in red blood cells. A complex hierarchy of regulation is emerging involving tissue-specific signals, chemical modifications to the DNA molecule and the proteins about which DNA is wrapped, enzymes that package and unpackage DNA and different cellular compartments that either favour or repress gene expression. Human genetic diseases are now being identified in which the components of this complex apparatus are disrupted. In one such condition, ATR-X syndrome, the affected children have profound learning difficulties, a characteristic facial appearance, abnormalities of genital development and a form of anaemia. It arises because of mutations in a protein involved in the regulation of gene expression. The diverse problems probably reflect the many different genes whose expression is perturbed. The overall aim of this programme is to determine the role of such proteins in the regulation of gene expression and their involvement in human disease.</gtr:abstractText><gtr:technicalSummary>In higher organisms, DNA is packaged in the cell nucleus as a protein /DNA complex, known as chromatin. In the last twenty years, the importance of chromatin-associated proteins in the regulation of gene expression has been established. One such class of proteins, chromatin remodellers, plays a role in altering the packaging and accessibility of DNA. Through the study of a form of syndromal mental retardation associated with a thalassaemia it is apparent that mutations in ATRX, a putative chromatin remodelling protein, can perturb normal a globin gene expression. The overall aim of this programme is to determine the role of such chromatin remodelling proteins in the regulation of gene expression and their involvement in human disease.||ATR-X syndrome comprises mental retardation, facial dysmorphism, urogenital and skeletal abnormalities and an unusual form of the anaemia, a thalassaemia. A thalassaemia arises when there is a defect in the synthesis of the a globin chains of adult haemoglobin (HbA, a2b2). ATR-X results from mutations in an X-encoded factor, ATRX. We have also shown that acquired, somatic mutations in ATRX are also associated with rare premalignant haematological condition, alpha thalassaemia myelodysplastic syndrome. Mutations in this gene down-regulate a gene expression and also perturb the expression of other, as yet unidentified genes.||To date, we have diagnosed over 150 cases of ATR-X and identified the mutations in majority of these. Analysis of these natural mutants has been one of the most powerful ways of elucidating the function of ATRX. In particular, it has helped define the phenotypic spectrum of the condition and the functional significance of predicted protein domains. Through this work we have collected an invaluable resource of patient cell lines and DNA samples which has facilitated our understanding of the pathophysiology of this condition. We will continue this diagnostic service through which potentially valuable and instructive new cases will be identified.||ATRX is a heterochromatic protein and mutations perturb the normal pattern of DNA methylation at diverse loci. In order to understand the role of ATRX in gene expression we need a better understanding of where and how ATRX is localised and the proteins with which it interacts and its normal repertoire of gene targets. We need a clearer idea of how ATRX effects methylation and the relationship of this to gene expression. We are developing model systems that are amenable to manipulation and allow us to more closely examine the role of ATRX in tissues (such as brain and bone marrow) not accessible in patients with ATR-X syndrome.||We have expressed the ATRX protein in vitro and can now start to analyse its function in a better defined and more precise manner. In addition we have developed a chromatin immunoprecipitation approach to identifying the direct targets of ATRX and thereby better understand how it identifies and modifies its targets. We are modifying DT40 cells and using mutants of the ATRX protein interaction domains to identify protein partners of ATRX. The widespread abnormalities in methylation in ATRX mutants presents one of the most intriguing puzzles. We plan to determine how mutations in ATRX produce abnormal patterns of methylation using newly developed models involving ES cells and iPS cells.||In order to understand the structural and functional consequences of the mutations that arise in the major protein domains, the structure of PHD-like domain has been determined in collaboration with Dr Daniela Rhodes (LMB, Cambridge). Further studies are underway to use these structures to analyse how ATRX may interact with chromatin.||Although the study of ATR-X patients has been extremely valuable in our initial understanding of the phenotype of ATR-X syndrome, for a thorough understanding of the role of ATRX and the pathophysiology associated with mutations of ATRX we require an animal model. We have been developed a mouse kn</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2225272</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Structural analysis of the ATRX ADD domain</gtr:description><gtr:id>EC3A1084-027A-487E-8D67-1FFA65E790D3</gtr:id><gtr:impact>17609377</gtr:impact><gtr:outcomeId>CiVE3krDkQN-1</gtr:outcomeId><gtr:partnerContribution>1 paper 17609377</gtr:partnerContribution><gtr:piContribution>Determination of disease causing mutations. Design and synthesis of protein constructs.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Western University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Characterisation of ATRX function in mouse brain</gtr:description><gtr:id>FB8DBE23-4874-4870-92F5-B67E4CA09813</gtr:id><gtr:impact>19020049</gtr:impact><gtr:outcomeId>krC3WydtPXS-1</gtr:outcomeId><gtr:partnerContribution>Characterisation of ATRX function in mouse brain</gtr:partnerContribution><gtr:piContribution>Provided ATRX knockout and floxed mouse</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rockefeller University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Laboratory of Chromatin Biology and Epigenetics Rockefeller</gtr:department><gtr:description>Role of ATRX in H3.3 deposition</gtr:description><gtr:id>784B8302-9B06-419B-ABFE-0013FF04D3F2</gtr:id><gtr:impact>Paper in Cell: 20211137</gtr:impact><gtr:outcomeId>SasS73eTPmm-1</gtr:outcomeId><gtr:partnerContribution>Paper in Cell: 20211137</gtr:partnerContribution><gtr:piContribution>Supplied ATRX knockout mouse ES cells, ATRX peptides and antibodies against ATRX</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ottawa</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Characterisation of ATRX function in mouse eye</gtr:description><gtr:id>26C76E9B-738B-408C-8604-3720961CE715</gtr:id><gtr:impact>19088125</gtr:impact><gtr:outcomeId>D63367945A3-1</gtr:outcomeId><gtr:partnerContribution>Characterisation of ATRX function in mouse eye</gtr:partnerContribution><gtr:piContribution>Provision of knockout and floxed ATRX mouse ATR-X syndrome data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rockefeller University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Role of ATRX in H3.3 deposition</gtr:description><gtr:id>69799FC8-B95E-4D57-A44A-58E37267AA8B</gtr:id><gtr:impact>Paper in Cell: 20211137</gtr:impact><gtr:outcomeId>bUFRVgDekG4-1</gtr:outcomeId><gtr:partnerContribution>Paper in Cell: 20211137</gtr:partnerContribution><gtr:piContribution>Supplied ATRX knockout mouse ES cells, ATRX peptides and antibodies against ATRX</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ottawa</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Ottawa Health Research Institute</gtr:department><gtr:description>Characterisation of ATRX function in mouse eye</gtr:description><gtr:id>EEDA4F7A-9A1C-426A-8706-9E5D37A35506</gtr:id><gtr:impact>19088125</gtr:impact><gtr:outcomeId>q8rApTeJQjK-1</gtr:outcomeId><gtr:partnerContribution>Characterisation of ATRX function in mouse eye</gtr:partnerContribution><gtr:piContribution>Provision of knockout and floxed ATRX mouse ATR-X syndrome data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Structural analysis of the ATRX ADD domain</gtr:description><gtr:id>46BC811F-FDD5-4AD4-86C8-AA32FECC06F3</gtr:id><gtr:impact>17609377</gtr:impact><gtr:outcomeId>8E88A35D826-1</gtr:outcomeId><gtr:partnerContribution>Determination of structure of ATRX ADD domain and effect of disease causing mutations on this domain</gtr:partnerContribution><gtr:piContribution>Determination of disease causing mutations. Design and synthesis of protein constructs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Western University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Characterisation of ATRX function in mouse brain</gtr:description><gtr:id>8DED5C8B-46D3-44CC-9A56-4C88BA5384C8</gtr:id><gtr:impact>19020049</gtr:impact><gtr:outcomeId>7449C6A4190-1</gtr:outcomeId><gtr:partnerContribution>Characterisation of ATRX function in mouse brain</gtr:partnerContribution><gtr:piContribution>Provided ATRX knockout and floxed mouse</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford Science Week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4ECD793A-7ACD-4AC3-BC51-CDD0932C2CAC</gtr:id><gtr:impact>Oxford Science week is an annual event and presentations are made to both scientists and the general public.

Considerable interest from those attending</gtr:impact><gtr:outcomeId>GS8U1Kkm7kg</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Student work experience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A3DABDDB-1759-4DD8-AE92-5ACD6B85BF2B</gtr:id><gtr:impact>School children aged 16-18 have the opportunity to work in the lab for a period of 1 week

Some have gone on to study medicine of biomedical sciences at University</gtr:impact><gtr:outcomeId>rKexroMD2HE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MHU Student Presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>81B6920F-EA7D-4051-95AA-550317FA0A9B</gtr:id><gtr:impact>2nd and 4th year MHU Students giving presentations on the work they are carrying out in the laboratory. These presentations will be held annually

Improve student training</gtr:impact><gtr:outcomeId>HbGYLMwy1VJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Student Presentations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9140C2A2-C5A0-4FDD-85D4-495C1426191F</gtr:id><gtr:impact>3rd year students present their work to the members of the Weatherall Institute of Molecular Medicine. This presentation day is held annually.

Improved student training</gtr:impact><gtr:outcomeId>3A062D344F2</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2nd Radcliffe Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B72AD6C4-4473-498C-8C93-0CB1D067DDAF</gtr:id><gtr:impact>XX</gtr:impact><gtr:outcomeId>58b96a59b408c2.31157978</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>213151</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fp7 Marie Curie Network - ITN</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>89BA5E23-EC4E-4259-AC3D-27D36991CD44</gtr:id><gtr:outcomeId>1D8716374370</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FP7 Marie Curie ITN</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>F4B23EC5-D4D5-4FC0-A993-6E67E8567204</gtr:id><gtr:outcomeId>TEqVYdu9gE40</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>211702</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Research Training Fellowship</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>6ABF6BEA-32D3-4C9C-93F9-2035501D58E1</gtr:id><gtr:outcomeId>1D5D9D266940</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The IP covers the Next Generation Capture-C method for massively multiplexed 3C analysis of genome interactions</gtr:description><gtr:grantRef>MC_U137961147</gtr:grantRef><gtr:id>7EF6D545-B398-4245-BD33-ED97FB17C9C9</gtr:id><gtr:impact>None so far</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58b82e1c2e1e38.60695333</gtr:outcomeId><gtr:patentId>PCT/GB2016/053314</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>NG Capture C</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ATR-X diagnostics</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4E2FFDDE-42B4-40BD-B749-82C70CE06003</gtr:id><gtr:impact>Characterisation of an important inherited cause of learning difficulties. Development of diagnostic test for this condition including prenatal diagnosis.</gtr:impact><gtr:outcomeId>NW1kTzeEFJ4</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mouse ATRX knockout and floxed model</gtr:description><gtr:id>06FED6DA-03BA-4808-BB2E-940890A4DC67</gtr:id><gtr:impact>17503331, 16628246, 19020049, 19088125, 20211137</gtr:impact><gtr:outcomeId>F1DEBC648F9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mouse ATRX knockout and floxed model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17503337</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines from affected individuals</gtr:description><gtr:id>33BAF507-0FA2-42FE-BD59-370CC84BB586</gtr:id><gtr:impact>Multiple publications</gtr:impact><gtr:outcomeId>fZFznusN3Y5</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ATR-X syndrome cell line collection</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of a functional test for ATR-X syndrome based on abnormal DNA methylation</gtr:description><gtr:id>3D9CC6A3-DFD3-4116-98CF-72199173FF84</gtr:id><gtr:impact>Identification of ATR-X syndrome in individuals negative using previous tests</gtr:impact><gtr:outcomeId>501AFFE0A30</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Improved functional diagnostic test for ATR-X syndrome</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>ATRX monoclonal antibodies</gtr:description><gtr:id>9F268FBA-0589-41BA-B6E2-CB868FFE8FA0</gtr:id><gtr:impact>Multiple publications</gtr:impact><gtr:outcomeId>SLaXmV9ZHBL</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ATRX monoclonal antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of a functional test for ATR-X syndrome based on abnormal DNA methylation</gtr:description><gtr:id>65FE924F-1BD5-4961-BDE9-B9172CD37D08</gtr:id><gtr:impact>Identification of ATR-X syndrome in individuals negative using previous tests</gtr:impact><gtr:outcomeId>mb2RsScAmsX</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Improved functional diagnostic test for ATR-X syndrome</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines from affected individuals</gtr:description><gtr:id>F12DABFC-E15C-4B0A-94EB-6BAB005AFA4A</gtr:id><gtr:impact>Multiple publications</gtr:impact><gtr:outcomeId>BF7A542EC70</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ATR-X syndrome cell line collection</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse ATRX knockout and floxed model</gtr:description><gtr:id>3CC497E7-F055-41BF-9B43-ADE449C28B35</gtr:id><gtr:impact>17503331, 16628246, 19020049, 19088125, 20211137</gtr:impact><gtr:outcomeId>qfUPAuiAXAx</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mouse ATRX knockout and floxed model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17503338</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>ATRX monoclonal antibodies</gtr:description><gtr:id>146785E6-4EE7-44BB-8A87-CEB96BC89396</gtr:id><gtr:impact>Multiple publications</gtr:impact><gtr:outcomeId>4D3BE82219B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ATRX monoclonal antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>93158AEF-DFE7-4DEF-90A3-D54009D27F9C</gtr:id><gtr:title>Gastrointestinal phenotype of ATR-X syndrome.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd11e59b608d617f2af46e4c9cc3a725"><gtr:id>cd11e59b608d617f2af46e4c9cc3a725</gtr:id><gtr:otherNames>Martucciello G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn><gtr:outcomeId>WkYzU6nWtnK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF262127-2931-4233-AEA5-90CB09DD2FBB</gtr:id><gtr:title>Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a34c1e449c183bb1e5e02ab1f8e0b9a4"><gtr:id>a34c1e449c183bb1e5e02ab1f8e0b9a4</gtr:id><gtr:otherNames>Steensma DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>NCKKT7g15tp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>114D1778-F80F-4A3B-8090-E34FD45157F6</gtr:id><gtr:title>Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca3bd30d9fd5f85dd44493aa3a988cd0"><gtr:id>ca3bd30d9fd5f85dd44493aa3a988cd0</gtr:id><gtr:otherNames>Eustermann S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>AoUHfTKGkCg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A1B67AC-659C-4333-884E-D2B5D1CDA695</gtr:id><gtr:title>Using genomics to study how chromatin influences gene expression.</gtr:title><gtr:parentPublicationTitle>Annual review of genomics and human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e9a17e3016005ab525dab981b1cf314"><gtr:id>1e9a17e3016005ab525dab981b1cf314</gtr:id><gtr:otherNames>Higgs DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1527-8204</gtr:issn><gtr:outcomeId>WvBUTJfaER2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B5A81D4-8416-4B15-ADF0-C5A77462F3D3</gtr:id><gtr:title>ATRX dysfunction induces replication defects in primary mouse cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fce217e81a00dce6e5d21eeb097f2a12"><gtr:id>fce217e81a00dce6e5d21eeb097f2a12</gtr:id><gtr:otherNames>Clynes D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5448b91a9da747.35137460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50428F99-F83E-477B-9698-0C9A2F43239D</gtr:id><gtr:title>The chromatin remodeller ATRX: a repeat offender in human disease.</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fce217e81a00dce6e5d21eeb097f2a12"><gtr:id>fce217e81a00dce6e5d21eeb097f2a12</gtr:id><gtr:otherNames>Clynes D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn><gtr:outcomeId>pm_13065_25_23916100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E39DB77-D3DB-4229-8447-5F329873C71F</gtr:id><gtr:title>A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/176b59cd6681e624045d11349b7b0e8d"><gtr:id>176b59cd6681e624045d11349b7b0e8d</gtr:id><gtr:otherNames>De Gobbi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>tj1DoZHdQVM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6863278F-4DA5-48F7-9158-66B1BF0CEBA9</gtr:id><gtr:title>ATRX Plays a Key Role in Maintaining Silencing at Interstitial Heterochromatic Loci and Imprinted Genes.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/461341f86b0010ce65b9c4daceda43e8"><gtr:id>461341f86b0010ce65b9c4daceda43e8</gtr:id><gtr:otherNames>Voon HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d03d3b30d975.84281615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29006634-D3B3-411E-ACC8-B1238C78DF0F</gtr:id><gtr:title>The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c28c456764709352f40d2dd6fba125f"><gtr:id>8c28c456764709352f40d2dd6fba125f</gtr:id><gtr:otherNames>Nguyen DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>5a994894207513.91499388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB4A7579-F135-44A8-8EE6-686968FE27B0</gtr:id><gtr:title>a-Thalassemia, mental retardation, and myelodysplastic syndrome.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f526570d3844b0ac238950732a090d"><gtr:id>b1f526570d3844b0ac238950732a090d</gtr:id><gtr:otherNames>Gibbons RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_13065_25_23028133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB98D4FA-A9B3-43F3-B3CF-E6FF65316A5E</gtr:id><gtr:title>The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS).</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7559b6b5e8b26bd2b1530ac9fbe4c955"><gtr:id>7559b6b5e8b26bd2b1530ac9fbe4c955</gtr:id><gtr:otherNames>Haas PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>ocJFSxEMfuq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47D0AC4B-9CA3-48B4-8E12-15DB3CA71648</gtr:id><gtr:title>Alpha thalassaemia-mental retardation, X linked.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/252af2121816d1321e9544916cd57745"><gtr:id>252af2121816d1321e9544916cd57745</gtr:id><gtr:otherNames>Gibbons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>CUkPoKmXU2R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C31F25-A472-4D52-8D5F-5B47B98327AA</gtr:id><gtr:title>Alpha thalassaemia-mental retardation, X linked.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/252af2121816d1321e9544916cd57745"><gtr:id>252af2121816d1321e9544916cd57745</gtr:id><gtr:otherNames>Gibbons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>6761710DA8D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84BCDD01-2EB7-477E-A964-5A741E50200B</gtr:id><gtr:title>Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fce217e81a00dce6e5d21eeb097f2a12"><gtr:id>fce217e81a00dce6e5d21eeb097f2a12</gtr:id><gtr:otherNames>Clynes D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d03d3c1ccfa1.05322420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>763CD766-7630-4D61-A4E6-0A860785804E</gtr:id><gtr:title>Maintaining memory of silencing at imprinted differentially methylated regions.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/461341f86b0010ce65b9c4daceda43e8"><gtr:id>461341f86b0010ce65b9c4daceda43e8</gtr:id><gtr:otherNames>Voon HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>585d530d49a5d6.86619336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F609E998-00C3-4760-907B-C850D175886F</gtr:id><gtr:title>Distinct factors control histone variant H3.3 localization at specific genomic regions.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b681063147f8df6b34dfde27a60c4f8"><gtr:id>2b681063147f8df6b34dfde27a60c4f8</gtr:id><gtr:otherNames>Goldberg AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>HrKooB2s1S6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5F0C3C9-AC0F-4484-AF8E-F9B447F8A4EE</gtr:id><gtr:title>Altered visual function and interneuron survival in Atrx knockout mice: inference for the human syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/793a2f179bace44a03e5feed6baed4c6"><gtr:id>793a2f179bace44a03e5feed6baed4c6</gtr:id><gtr:otherNames>Medina CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>503F7FF1AD7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFA8A04C-0A53-4583-A8CE-1AF7F3687ECB</gtr:id><gtr:title>Mutations in the chromatin-associated protein ATRX.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f526570d3844b0ac238950732a090d"><gtr:id>b1f526570d3844b0ac238950732a090d</gtr:id><gtr:otherNames>Gibbons RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>ny48N9ZFaUA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E17AAD75-EA17-4E64-B784-2476470F0A4C</gtr:id><gtr:title>Tissue-specific histone modification and transcription factor binding in alpha globin gene expression.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/176b59cd6681e624045d11349b7b0e8d"><gtr:id>176b59cd6681e624045d11349b7b0e8d</gtr:id><gtr:otherNames>De Gobbi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>f5R2EHw5Nac</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29B92E10-CDBE-4B9F-A2A9-D218C81B7DAC</gtr:id><gtr:title>Mutations in the chromatin-associated protein ATRX.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f526570d3844b0ac238950732a090d"><gtr:id>b1f526570d3844b0ac238950732a090d</gtr:id><gtr:otherNames>Gibbons RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>9A37E289EE9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69B32122-92C7-4317-9CA0-4935FF20A30B</gtr:id><gtr:title>ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/708f25fff3a52f9240891fd7c618e5d6"><gtr:id>708f25fff3a52f9240891fd7c618e5d6</gtr:id><gtr:otherNames>Law MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>CejBzSCLEn6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>911203F2-E9C6-4893-8C1E-5F614A753D47</gtr:id><gtr:title>An interspecies analysis reveals a key role for unmethylated CpG dinucleotides in vertebrate Polycomb complex recruitment.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf85181d460d7697454708928c59a0c"><gtr:id>fcf85181d460d7697454708928c59a0c</gtr:id><gtr:otherNames>Lynch MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>fWdkjxzHaNV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B092ADC3-25EE-4F6C-86A8-061BBFBF78A3</gtr:id><gtr:title>Genetic dissection of the a-globin super-enhancer in vivo.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4372a7f2d5ea1d6313b49e5c539a538"><gtr:id>f4372a7f2d5ea1d6313b49e5c539a538</gtr:id><gtr:otherNames>Hay D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58b6af648844e9.80201951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F372DDC9-CF31-44BA-9CFE-9D2C857F991D</gtr:id><gtr:title>Gastrointestinal phenotype of ATR-X syndrome.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd11e59b608d617f2af46e4c9cc3a725"><gtr:id>cd11e59b608d617f2af46e4c9cc3a725</gtr:id><gtr:otherNames>Martucciello G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn><gtr:outcomeId>1B8FDC4E0EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0691502F-3CFF-4160-AF7D-05DE43EECFB9</gtr:id><gtr:title>A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome.</gtr:title><gtr:parentPublicationTitle>European journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecf0e0a08aaad835b94aa5a80436ae49"><gtr:id>ecf0e0a08aaad835b94aa5a80436ae49</gtr:id><gtr:otherNames>Costa DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0902-4441</gtr:issn><gtr:outcomeId>W63XUy8xyz7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A774C96-4FE2-4C66-9AEF-8E839C5D1E63</gtr:id><gtr:title>ATRX: taming tandem repeats.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f526570d3844b0ac238950732a090d"><gtr:id>b1f526570d3844b0ac238950732a090d</gtr:id><gtr:otherNames>Gibbons RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>djcvt3FUrg4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6866BB6D-D320-444B-A372-3FB87B66AC72</gtr:id><gtr:title>Structural consequences of disease-causing mutations in the ATRX-DNMT3-DNMT3L (ADD) domain of the chromatin-associated protein ATRX.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b478d5235b8c6069d0ed8d91c32c87f2"><gtr:id>b478d5235b8c6069d0ed8d91c32c87f2</gtr:id><gtr:otherNames>Argentaro A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>CktUts22oZz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>702D30C7-EEDE-49E3-A0FC-C0FE5E8A9CA7</gtr:id><gtr:title>Neuronal death resulting from targeted disruption of the Snf2 protein ATRX is mediated by p53.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0487957c0eb08db37f1c97b89840d2c0"><gtr:id>0487957c0eb08db37f1c97b89840d2c0</gtr:id><gtr:otherNames>Seah C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>U6awwnF1LRj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2680DAF-D8BA-428C-A2FF-7021352958BB</gtr:id><gtr:title>X-linked alpha thalassaemia/mental retardation syndrome: a case with gonadal dysgenesis, caused by a novel mutation in ATRX gene.</gtr:title><gtr:parentPublicationTitle>Clinical dysmorphology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f067d80044230e4f83ac7410b3b159d1"><gtr:id>f067d80044230e4f83ac7410b3b159d1</gtr:id><gtr:otherNames>Jezela-Stanek A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0962-8827</gtr:issn><gtr:outcomeId>AeRue1kb35y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F601ADC8-AA3C-4546-A0E9-5D26F54BF6D9</gtr:id><gtr:title>Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99ac403c7fa258a68b80b7fdbbec57e2"><gtr:id>99ac403c7fa258a68b80b7fdbbec57e2</gtr:id><gtr:otherNames>Giardine B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>jb44CSSwaYW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7FEE27B-CBFF-4BBA-95EA-6491130740DE</gtr:id><gtr:title>Loss of Atrx affects trophoblast development and the pattern of X-inactivation in extraembryonic tissues.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b62f919c1ce48564e23cc6ba86f4ad99"><gtr:id>b62f919c1ce48564e23cc6ba86f4ad99</gtr:id><gtr:otherNames>Garrick D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>LwUrKNgNJJQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C3D3A73-DA4D-4E21-ADBE-72E456583338</gtr:id><gtr:title>Functional significance of mutations in the Snf2 domain of ATRX.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cd3ca91810ebfbda5aaf1fe5470d48b"><gtr:id>1cd3ca91810ebfbda5aaf1fe5470d48b</gtr:id><gtr:otherNames>Mitson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>hqYvyubKL9J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84898B52-138A-48AC-916F-CBB741D04CDE</gtr:id><gtr:title>The molecular basis of a-thalassemia: a model for understanding human molecular genetics.</gtr:title><gtr:parentPublicationTitle>Hematology/oncology clinics of North America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e9a17e3016005ab525dab981b1cf314"><gtr:id>1e9a17e3016005ab525dab981b1cf314</gtr:id><gtr:otherNames>Higgs DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0889-8588</gtr:issn><gtr:outcomeId>EBHw68Cvvtq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E510CC24-FE64-4347-BED3-2CCA5FD5914A</gtr:id><gtr:title>Generation of bivalent chromatin domains during cell fate decisions.</gtr:title><gtr:parentPublicationTitle>Epigenetics &amp; chromatin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/176b59cd6681e624045d11349b7b0e8d"><gtr:id>176b59cd6681e624045d11349b7b0e8d</gtr:id><gtr:otherNames>De Gobbi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1756-8935</gtr:issn><gtr:outcomeId>mXjLote6oz8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82C3A453-F229-4878-8CB7-4AC93DD232D5</gtr:id><gtr:title>X-linked alpha thalassaemia/mental retardation syndrome: a case with gonadal dysgenesis, caused by a novel mutation in ATRX gene.</gtr:title><gtr:parentPublicationTitle>Clinical dysmorphology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f067d80044230e4f83ac7410b3b159d1"><gtr:id>f067d80044230e4f83ac7410b3b159d1</gtr:id><gtr:otherNames>Jezela-Stanek A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0962-8827</gtr:issn><gtr:outcomeId>4EC964FB19F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDA492AC-D458-4A84-8872-E5783D8E1F00</gtr:id><gtr:title>Defining the cause of skewed X-chromosome inactivation in X-linked mental retardation by use of a mouse model.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48237da23a0f64a5f2ba71ec22b9273a"><gtr:id>48237da23a0f64a5f2ba71ec22b9273a</gtr:id><gtr:otherNames>Muers MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>Ve6ZqirMKJT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2D09A08-33C2-47DC-BEC4-720BA17AB2AC</gtr:id><gtr:title>Altered visual function and interneuron survival in Atrx knockout mice: inference for the human syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/793a2f179bace44a03e5feed6baed4c6"><gtr:id>793a2f179bace44a03e5feed6baed4c6</gtr:id><gtr:otherNames>Medina CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>mAUH7HNdSYU</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137961147</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>